Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.68 USD | +0.98% | -1.28% | -17.69% |
04-24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
04-23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.69% | 11.6B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-43.00% | 11.51B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Says FDA Accepts New Drug Application for Priority Review for Treating Two Forms of Cancer, Standard Review for a Third